Vera Therapeutics Ownership | Who Owns Vera Therapeutics?
Vera Therapeutics Ownership Summary
Vera Therapeutics is owned by 66.84% institutional investors, 1.21% insiders, and 31.96% retail investors. Avoro capital advisors is the largest institutional shareholder, holding 9.74% of VERA shares. T. Rowe Price Health Sciences is the top mutual fund, with 2.77% of its assets in Vera Therapeutics shares.
VERA Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Vera Therapeutics | 66.84% | 1.21% | 31.96% |
| Sector | Healthcare Stocks | 232.01% | 10.74% | -142.75% |
| Industry | Biotech Stocks | 381.47% | 10.55% | -292.02% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Avoro capital advisors | 6.21M | 9.74% | $180.46M |
| Blackrock funding, inc. /de | 4.83M | 7.56% | $244.36M |
| Blackrock | 3.34M | 6.55% | $120.76M |
| Kynam capital management, lp | 4.03M | 6.31% | $117.05M |
| Price t rowe associates inc /md/ | 3.67M | 5.75% | $106.55M |
| Deerfield management company, l.p. (series c) | 3.64M | 5.71% | $105.81M |
| Vanguard group | 3.57M | 5.59% | $180.81M |
| Fmr | 2.84M | 4.46% | $82.62M |
| Eversept partners, lp | 2.81M | 4.40% | $81.60M |
| Sofinnova investments | 2.79M | 4.38% | $81.19M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Kynam capital management, lp | 4.03M | 8.71% | $117.05M |
| Tri locum partners lp | 1.19M | 7.95% | $34.59M |
| Eversept partners, lp | 2.81M | 5.62% | $81.60M |
| Portman | 32.80K | 4.48% | $1.19M |
| Sofinnova investments | 2.79M | 4.44% | $81.19M |
| Integral health asset management | 1.70M | 3.34% | $49.40M |
| Exome asset management | 156.07K | 2.75% | $4.54M |
| Bioimpact capital | 563.08K | 2.68% | $16.36M |
| Avoro capital advisors | 6.21M | 2.33% | $180.46M |
| Rhenman & partners asset management ab | 420.00K | 1.99% | $21.27M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Point72 asset management | 1.27M | 0.06% | 1.27M |
| Tri locum partners lp | 1.19M | 7.95% | 777.09K |
| Kynam capital management, lp | 4.03M | 8.71% | 600.91K |
| Blackrock funding, inc. /de | 4.83M | 0.00% | 578.33K |
| Integral health asset management | 1.70M | 3.34% | 550.00K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Vestal point capital, lp | 760.00K | 1.00% | -2.34M |
| Holocene advisors, lp | - | - | -2.20M |
| Woodline partners lp | 737.58K | 0.10% | -1.87M |
| T. rowe price investment management | - | - | -1.68M |
| Paradigm biocapital advisors lp | - | - | -1.44M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Point72 asset management | 1.27M | 0.06% | 1.27M | $36.97M |
| Pfm health sciences, lp | 513.68K | 1.15% | 513.68K | $14.93M |
| Braidwell lp | 472.74K | 0.41% | 472.74K | $13.74M |
| Hsbc | 297.02K | 0.00% | 297.02K | $8.63M |
| Timessquare capital management | 252.46K | 0.19% | 252.46K | $12.78M |
Sold Out
| Holder | Change |
|---|---|
| Ifp advisors | -6.00 |
| Geowealth management | -6.00 |
| Coldstream capital management | -6.00 |
| Nelson, van denburg & campbell wealth management group | -7.00 |
| Capital performance advisors llp | -11.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 146 | -19.34% | 42,673,172 | -34.42% | 66 | 0.64% | 91 | -9.90% | 42 | -12.50% |
| Sep 30, 2025 | 175 | -0.57% | 63,626,863 | 5.34% | 99 | 1.11% | 96 | -6.80% | 46 | -2.13% |
| Jun 30, 2025 | 184 | 0.55% | 63,880,155 | 2.67% | 100 | 1.05% | 108 | 9.09% | 47 | -4.08% |
| Mar 31, 2025 | 186 | 1.64% | 62,983,082 | 0.11% | 98 | 0.75% | 101 | -20.47% | 50 | 35.14% |
| Dec 31, 2024 | 174 | -2.25% | 59,594,280 | 11.34% | 108 | 1.14% | 121 | 26.04% | 35 | -30.00% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| T. Rowe Price Health Sciences | 1.97M | 2.77% | 747.49K |
| Vanguard Total Stock Mkt Idx Inv | 1.88M | 2.65% | 5.32K |
| Fidelity Growth Compy Commingled Pl O | 1.16M | 2.11% | - |
| Vanguard US Total Market Shares ETF | 1.33M | 2.09% | -2.90K |
| State Street® SPDR® S&P® Biotech ETF | 1.48M | 2.09% | -7.92K |
| iShares Russell 2000 ETF | 1.34M | 1.89% | 1.06M |
| Fidelity Growth Compy Commingled Pl S | 1.20M | 1.69% | 1.29K |
| T. Rowe Price New Horizons | 1.14M | 1.60% | 99.65K |
| US Small-Cap Growth II Equity Comp | 1.14M | 1.60% | 245.92K |
| Pictet-Biotech P USD | 989.71K | 1.39% | 121.48K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Feb 23, 2026 | Brenner Robert | Chief Medical Officer | Sell | $90.31K |
| Feb 23, 2026 | Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | Sell | $130.86K |
| Feb 23, 2026 | Grant Sean | CHIEF FINANCIAL OFFICER | Sell | $207.78K |
| Feb 23, 2026 | Fordyce Marshall | PRESIDENT AND CEO | Sell | $710.58K |
| Feb 23, 2026 | JOHNSON DAVID LEE | Chief Operating Officer | Sell | $108.28K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q1 | - | 7 |
| 2025 Q4 | 1 | 5 |
| 2025 Q2 | 4 | - |
| 2025 Q1 | - | 6 |
| 2024 Q4 | - | 31 |
VERA Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools